Malaria future or investigational therapies

Jump to navigation Jump to search

Malaria Microchapters

Home

Patient Information

Overview

Historical perspective

Classification

Pathophysiology

Causes

Differentiating Malaria from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Xray

Ultrasound

CT scan

MRI

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case studies

Case #1

Malaria future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Malaria future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Malaria future or investigational therapies

CDC on Malaria future or investigational therapies

Malaria future or investigational therapies in the news

Blogs on Malaria future or investigational therapies

Directions to Hospitals Treating Malaria

Risk calculators and risk factors for Malaria future or investigational therapies

Future or Investigational Therapies

Anti-Malaria Vaccine

In October 2005, Malaria Vaccine Initiative PATH (MVI/PATH) partnered with Glaxosmithkline, a pharmaceutical company, to develop an anti-malaria vaccine, using a grant by Bill & Melinda Gates Foundation.

The vaccine, called "GSK RTS,S/AS01" was administered with other vaccines included in Expanded Programme on Immunization (EPI). It includes 2 proteins: RTS and S. It is produced by S. cerevisiae species. The project ended in December 2014 with the publishing of two phase 3 trial reports in 2011 and 2012. The "RTS,S/AS01" vaccine affects the pre-erythrocytic stage of "P. falciparum" in young (5-17 months old) African children.[1] The authors concluded in 2011, after 12 months of follow-up, that the candidate vaccine has an efficacy against clinical and severe malaria of 55.8% and 47.3%, respectively.[1] In cases of severe malaria in children between 6 to 12 weeks of age, the efficacy was less. In 2012, infants 6-12 weeks of age were enrolled. The study showed that the vaccine efficacy against all clinical malaria was 32.9% and against severe malaria was 29%.[1]

References

  1. 1.0 1.1 1.2 RTS,S Clinical Trials Partnership. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG; et al. (2012). "A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants". N Engl J Med. 367 (24): 2284–95. doi:10.1056/NEJMoa1208394. PMID 23136909.

Template:WikiDoc Sources